Cambrex Grows Its Biopharma Offerings

Cambrex, a contract development and manufacturing organization (CDMO) that offers drug substance, drug product and analytical services across the entire drug lifecycle, will be expanding its current biopharma testing services business. The expansion consists of 11 additional current good manufacturing practice (cGMP) laboratories at Cambrex’s Durham, NC facility, and as company executives note, widens its service offering for large molecule and viral/cell-based therapeutics.

“We are excited to be adding to our fast-growing biopharmaceutical services business,” says Cambrex CEO Thomas Loewald. “Building upon the strength of our analytical team in Durham, this expansion enables us to increase our capacity to serve the large and growing biologics market, supporting the development and testing of a rapidly growing pipeline of large molecule therapeutics.”

These new capabilities apply to a wide variety of biopharmaceutical therapeutics, including bacteriophage and mammalian viruses, recombinant proteins, monoclonal antibodies, and nucleic acids.

The expansion includes a variety of instruments supporting nanoparticle size analysis, imaging, qPCR, fluorescent/absorbance plate readers, immunoblotting, mass spectrometry, next-generation sequencing (NGS), chromatography capillary electrophoresis (CE-PDA and FLD), SEC-MALS, and other compendial testing.

Last October, the CDMO invested over $30 million toward a manufacturing center of excellence project at its High Point, NC location.